Pieris and Sanofi (France) (SAN.PA) Broaden Existing Collaboration
4/10/2013 11:37:20 AM
More...
|
Pieris Presents Data and Reveals Targets for Anticalin® Bispecific PRS-190 at European Antibody Congress
11/29/2012 9:46:50 AM
More...
|
Pieris Achieves First Milestone Payment in Daiichi Sankyo, Inc. (4568.t) Collaboration to Develop Anticalin® Therapeutics
10/9/2012 11:01:37 AM
More...
|
Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin® at the American Association for Cancer Research Annual Meeting
4/4/2012 9:52:40 AM
More...
|
Pieris Receives BMBF Grant to Fund PRS-110c-Met Antagonist Anticalin(R) Program
2/7/2012 9:56:05 AM
More...
|
Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at American Society of Hematology Annual Meeting
12/13/2011 10:21:31 AM
More...
|
Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
11/15/2011 10:53:01 AM
More...
|
Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin(R) Pipeline Development
10/19/2011 10:09:52 AM
More...
|
Pieris Release: EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
10/19/2011 10:04:33 AM
More...
|
Pieris and Daiichi Sankyo, Inc. (D4S.F) Sign EUR 207 Million Therapeutic Collaboration to Develop Anticalin(R) Therapeutics
4/12/2011 8:13:55 AM
More...
|
|